Cite
HARVARD Citation
Berenson, J. et al. (2022). A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematological oncology. 40 (5), pp. 906-913. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Berenson, J. et al. (2022). A phase 1 study of ruxolitinib, steroids and lenalidomide for relapsed/refractory multiple myeloma patients. Hematological oncology. 40 (5), pp. 906-913. [Online].